At the beginning of September, Velocity Clinical Research topped Business North Carolina’s 2024 Fast 40 list. It was our third time receiving the award, which recognizes the fastest-growing mid-market businesses in the state. For a clinical trials organization to achieve this level of scale … Read more
In his latest article for the Association of Clinical Research Professionals (ACRP), Paul Evans outlines how integrated site organizations can pave the way for AI adoption and generate tangible value for the industry. For sites, investigators, and patients, Gen AI has the potential to … Read more
The pandemic left many notable developments in its wake, not least the increased focus on improving diversity in clinical trials. This issue was thrust into the spotlight during Operation Warp Speed — the accelerated development of a COVID-19 vaccine in the U.S. — and … Read more
As Nick Spittal states in this Advarra press release, membership in the Gene Therapy Ready (GTR) site network “allows Velocity to start studies over a month faster and provides a meaningful credential and important validation that increases sponsors’ confidence in our specialized capabilities to … Read more
Another major milestone for Velocity — more than $2.5 million in patient study stipends have been paid globally through our VISION Engage app! With VISION Engage, patients can seamlessly manage their trial journey while receiving study stipends directly through the app, making participation more … Read more
Congratulations to Henrik Watz, MD, PhD, and our site in Ahrensburg (formerly Velocity Grosshansdorf), Germany, which is currently the top enroller for a global COPD trial! Dr. Watz has just published his 250th full paper, detailing results from the Phase 2 AIRLEAF trial. This … Read more
Kris Kowdley, MD, AGAF, FAASLD, FACP, FACG, played an integral role in the clinical research that first gained FDA approval in June 2024, and has now led to the European Union’s approval of Ipsen’s Iqirvo, a groundbreaking therapy for primary biliary cholangitis (PBC), a … Read more
Velocity sites and investigators have now supported research for 12 products that received U.S. FDA approval in 2024! This year’s groundbreaking approvals include: Ebglyss (lebrikizumab-lbkz) by Eli Lilly, a new treatment for moderate to severe atopic dermatitis (eczema). mRESVIA by Moderna, a vaccine to … Read more
In this new article for VentureBeat, Raghu Punnamraju, Chief Technology Officer at Velocity, discusses why data science alone is not enough to ensure product success. In this insightful piece, Raghu explores the importance of blending technical excellence with commercial understanding, highlighting the need for … Read more
Paul Evans was recently featured in a Business North Carolina article discussing the emerging impact of artificial intelligence on North Carolina’s clinical research industry. As Paul notes, “Our industry is in the same place as most people with AI. We’ve seen a step change. … Read more
Brandon Essink, MD, CPI, and J. Scott Overcash, MD, were authors of a recent Nature Communications article, “Long-term safety and effectiveness of mRNA-1273 vaccine in adults: COVE trial open-label and booster phases.” From the article: “Boosting elicited greater immune responses against SARSCoV-2 than primary … Read more
Since launching in-app stipend payments, Velocity has paid more than $2 million to patients globally through VISION. The mobile app has also contributed to more than 2,500 patient randomizations, empowering users to get matched with clinical trials, self-screen, and self-schedule visits, all at times … Read more
Learn more about Velocity's capabilities
Whether you’re ready to conduct a single-site study or a complex, high-volume trial, Velocity will ensure you have the right investigators, clinical staff, and patients for your research program.
Join a remarkable team doing remarkable work
Velocity careers offer competitive pay and benefits, and reward high performance with excellent opportunities.
Whether you're an industry veteran or are looking to take your first step into clinical research, we invite you to apply at Velocity.